Trellus Health (LSE:TRLS) has secured an unsecured loan of $260,000 from Mount Sinai Health System to provide additional liquidity while the company continues to address financial challenges and evaluate strategic alternatives. The financing is expected to extend the group’s available cash resources until 31 July 2026.
Under the terms of the agreement, the loan will accrue interest at an annual rate of 8% beginning in December 2026. Repayment is due by June 2027, although the balance would become payable within 90 days should the company complete a sale of its U.S. subsidiary, Trellus Health Inc.
The transaction has been classified as a related party arrangement and was reviewed by the company’s independent directors, who concluded that the terms are fair and reasonable following consultation with Trellus Health’s nominated adviser. The additional funding arrives as the board continues to explore restructuring initiatives and strategic options aimed at strengthening the company’s financial position.
Trading in Trellus Health shares remains suspended on AIM while the company seeks greater clarity regarding its financial outlook. Management is assessing a range of potential outcomes, including restructuring measures and possible corporate transactions, such as the sale of its U.S. operations, in an effort to preserve value for stakeholders.
The company’s outlook continues to be weighed down by weak financial performance, including substantial ongoing losses, negative free cash flow and declining equity. The absence of debt provides some balance-sheet support, while technical indicators remain one of the few positive factors, with the shares previously demonstrating strong momentum above major moving averages. Valuation metrics remain constrained by the company’s loss-making position and lack of a dividend.
More About Trellus Health plc
Trellus Health plc is a healthcare technology company focused on delivering value-based digital care solutions for individuals living with complex chronic conditions. The company’s approach combines behavioural science, technology and personalised support to help patients improve health outcomes and reduce the long-term costs associated with chronic disease management.
Its flagship platform, Trellus Elevate, incorporates a proprietary resilience-based methodology, data analytics tools and expert coaching to support patients with gastrointestinal conditions such as inflammatory bowel disease. The company also offers Trellus TrialSet, a solution designed to support pharmaceutical companies across clinical development programmes and commercialisation initiatives.
Leave a Reply